Replimune Group, Inc. (NASDAQ:REPL) Receives $8.12 Average Target Price from Analysts

Replimune Group, Inc. (NASDAQ:REPL) has received an average recommendation of “Hold” from the ten research firms that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, six have given a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $8.1250.

Several equities research analysts have recently commented on the stock. Wall Street Zen upgraded shares of Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd. Piper Sandler downgraded shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price target for the company. in a report on Friday, April 10th. Wedbush boosted their price target on shares of Replimune Group from $6.00 to $9.00 and gave the company a “neutral” rating in a research report on Tuesday, June 30th. BMO Capital Markets raised shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective on the stock in a research note on Tuesday, June 30th. Finally, HC Wainwright reaffirmed a “sell” rating on shares of Replimune Group in a report on Monday, April 13th.

Insiders Place Their Bets

In other news, insider Christopher Sarchi sold 12,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the sale, the insider owned 180,962 shares in the company, valued at approximately $1,672,088.88. This represents a 6.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

Hedge funds have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC bought a new position in shares of Replimune Group in the fourth quarter worth about $29,000. CWM LLC grew its stake in shares of Replimune Group by 248.6% during the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after purchasing an additional 2,886 shares during the last quarter. Essential Partners LLC increased its holdings in shares of Replimune Group by 562,400.0% in the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after purchasing an additional 5,624 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Replimune Group by 37.5% in the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after purchasing an additional 1,879 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Replimune Group in the 2nd quarter worth approximately $69,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Price Performance

Replimune Group stock opened at $11.51 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.79 and a quick ratio of 4.79. The company has a market capitalization of $966.15 million, a PE ratio of -3.41 and a beta of 0.86. Replimune Group has a one year low of $1.50 and a one year high of $13.24. The business has a 50 day simple moving average of $7.51 and a 200 day simple moving average of $7.35.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). On average, sell-side analysts forecast that Replimune Group will post -2.25 EPS for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.